At the news
? NEUTRALIMPACT 3/10 6-K filed Nov 5, 2026 at 08:45 ET
Ping An Biomedical entered a definitive agreement to acquire three tumor cell-related medical technology patents from Future Biotechnology Group for $2.3 million. The acquisition is positioned as a long-term capacity-building move, not a near-term revenue driver, and the company continues to advance negotiations for a strategic investment in the seller.
- Definitive purchase agreement for three tumor cell-related patents at $2.3 million
- Patents cover oncology diagnosis/treatment, cell detection/bioengineering, biomarker/DNA probe technologies
- Company states the acquisition is not a near-term revenue driver but a capacity-building move
- Separately, negotiations continue for a proposed strategic investment in Future Biotechnology Group
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access